Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie today announced the acquisition of Mitokinin, a privately held biotechnology company focused on the discovery and development of selective…
AbbVie has bought Mitokinin, a closely held biotech developing experimental treatments for Parkinson's disease that target a gene called PINK1. Mitokinin…
AbbVie has agreed to acquire Mitokinin, a privately held biotech developing PINK1 mitochondrial kinase activators for Parkinson's disease, in a transaction…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
AbbVie acquired Mitokinin, gaining its PINK1 mitochondrial kinase activator program for Parkinson's disease. Mitokinin shareholders received $110M upfront with up to $545M in additional milestone payments contingent on PINK1 program development.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Mitokinin, Inc. (this deal) | 2023 | $655M | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2023 deals · AbbVie Inc. deals · Neurology deals